A multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis has been stopped for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine had worse outcomes than those who received placebos.